Delmar pharmaceuticals, inc. (DMPI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Cash flows from operating activities
Loss for the year

-

-

-1,605

-

-

-

-1,991

-2,377

-2,933

-3,161

-2,666

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-1,868

-1,321

-2,290

14,273

-1,140

-2,646

-1,621

-124

-2,086

-619

-1,516

399

-3,198

865

-6,794

-6,813

-7,405

-3

-4

-0

-3

-10

-3

-6

-3

-14

-7

Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets

2

2

2

2

2

4

6

6

6

5

5

5

3

3

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

2

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2

2

2

2

2

1

1

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

432

-0

1

-0

2

2

-0

56

187

-77

361

-225

-1,398

276

-680

-539

1,079

-781

892

-562

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

8

-2

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,432

-1,599

-372

-8,094

-4,599

-2,543

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability due change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

7

242

21

0

0

143

-167

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for services

4

3

4

3

3

2

4

-

-

-

0

0

0

0

564

66

0

80

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Performance stock unit expense

-

-

-

342

60

61

61

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

-

-

-

37

156

0

-1

-

-

-

50

247

218

174

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued to Valent for royalty reduction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

598

-

-

-

-

-

-

-

-

-

-

Non-cash derivative issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-2,201

-

-

-

-

-

-

-

-

-

-

Units issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Warrants issued for patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

15

108

0

0

-

-

-

-

-

-

-

-

-

-

Stock option expense

96

159

50

70

99

122

132

65

137

228

64

18

149

-75

31

255

23

74

39

-136

62

211

48

273

620

340

285

1,247

272

-

-

-

-

-

-

-

-

-

-

Prototype drug product

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net income (loss) after adjustments of non-cash items

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,086

-1,064

-1,069

-868

-977

-880

-903

-964

-1,787

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Prepaid expenses and deposits

-8

-100

-56

40

-66

-524

-203

-37

-67

-75

8

1,088

-11

-46

33

58

-82

-14

-63

-3

93

-6

-72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest, taxes and other receivables

-20

-40

44

17

-1

-1

-27

-22

37

-15

-36

6

52

-20

19

-13

15

-19

9

-23

34

-5

9

-0

-0

-0

-5

-60

31

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-34

98

-24

-26

137

54

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

334

-376

-616

627

-4

147

-568

-412

61

390

255

390

276

109

-178

-62

167

106

-389

276

229

-37

49

-159

263

-70

-220

-147

-98

-

-

-

-

-

-

-

-

-

-

Related party payables

19

65

-113

211

-39

-15

7

37

-275

311

-2

18

-135

128

32

14

-27

17

-52

47

5

-4

-13

19

-73

-108

-19

-59

-151

-

-

-

-

-

-

-

-

-

-

Total changes in non-cash working capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-107

29

-98

-80

92

570

-208

-

-336

-

-

-

-

-

-

-

-

-

-

Accounts Receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

5

-5

-

-

-

Accounts Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

0

2

0

0

0

0

-0

Net cash used in operating activities

-1,372

-1,709

-2,266

-1,812

-1,464

-964

-2,084

-2,532

-2,812

-2,132

-2,372

-

-

-

-

-

-956

-1,233

-1,401

-808

-979

-1,093

-971

-

-

-

-

-

-

-1

-4

-0

-3

-8

1

-11

-3

-14

-8

Net proceeds from the issuance of units

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

9,639

-

-

-

-

-

-

-

-

-

-

Series A preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows from operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,449

-1,613

-

-

-

-

-

-

-

-

-973

-884

-1,034

-1,112

-1,249

-2,124

-

-

-

-

-

-

-

-

-

-

Net cash flows from investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Cash flows from financing activities
Net proceeds from the issuance of shares and warrants

0

0

6,582

-

-

-

-

0

0

0

8,945

7,932

0

0

0

0

0

0

2,453

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the exercise of warrants

0

0

26

-

-

-

-

-

-

-

-

0

218

69

256

-

-

-

-

0

138

738

527

2,258

221

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Series A preferred stock dividend

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-2

-2

6,607

3,379

-85

782

-2

-2

310

-2

8,943

-

-

-

-

-

-62

403

2,451

-443

27

736

527

-

-

-

-

-

-

5

2

0

5

2

0

0

-

-

-

Proceeds of loan from officer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

Proceeds of loan from officer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-

-

-

0

-

-

-

-

Net proceeds from the issuance of common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

Net cash flows from financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

67

254

-

-

-

-

-

-

-

-

2,258

221

0

0

0

9,639

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-1,374

-1,712

4,341

1,566

-1,550

-182

-2,087

-2,534

-2,514

-2,134

6,570

4,485

-1,316

-1,381

-1,358

5,219

-1,019

-847

1,049

-1,252

-951

-357

-443

1,285

-662

-1,034

-1,112

-1,249

7,515

-

-

-

-

-

-

-

-

-

-

Issuance of preferred shares for the settlement of the loan payable to Valent (note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

278

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

728

319

72

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of stock option liability upon the forfeiture of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

38

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred costs recognized as equity issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares for the settlement of accounts payable (notes 7 and 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Issuance of units for the settlement of accounts payable (notes 8 and 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Non-cash share issuance costs (note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

6,288

-

-

-

-

-

-

-

-

-

-

Cashless exercise of Placement Agent Warrants (note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

239

0

0

-

-

-

-

-

-

-

-

-

-

Settlement of accounts payable with a loan payable (note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Exercise of CA$0.50 warrants for no additional consideration (note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

17

15

226

0

0

-

-

-

-

-

-

-

-

-

-

Deferred costs (note 9(f))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

90

-

-

-

-

-

-

-

-

-

-

Effects of exchange rates on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Net increase/ (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-1

-0

1

-4

0

0

-3

-14

-8

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Income Taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-